Spineart Secures $31M To Boost Spine Surgery Innovations
Swiss biotech company Spineart SA said on Friday that it has raised 25 million Swiss francs ($31.2 million) from European private equity firms Gimv NV and EGS Beteiligungen AG to help...To view the full article, register now.
Already a subscriber? Click here to view full article